Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +65

Is Abbott Laboratories (ABT) Now Offering Value After Recent Share Price Weakness?

AI-generated analysis

📉 Abbott Laboratories (ABT) shares have declined significantly, dropping 29.9% year-to-date and 33.7% over the last year despite no single company-specific event driving the drop.

💵 The stock recently traded at approximately US$87.01 per share, which analysts are evaluating for potential value after recent weakness.

🏥 Headlines focus on Abbott's position in medical devices and diagnostics, along with broader sector sentiment affecting healthcare stocks generally.

📊 On a 6-point valuation checklist from Simply Wall St, Abbott scores a high 5 out of 6 points indicating strong fundamental quality.

💰 A Discounted Cash Flow (DCF) model estimates an intrinsic value of $135.30 per share based on projected future cash flows extending to 2035.

📉 Based on the DCF analysis, the stock is considered undervalued by approximately 35.7% compared to its recent trading price.

📈 Abbott currently trades at a Price-to-Earnings (P/E) ratio of 24.24x, which is lower than its proprietary Fair Ratio estimate of 30.37x.

🤝 The P/E multiple is also below the peer group average of 33.24x, though it aligns closely with the broader Medical Equipment industry average of 23.87x.

💡 Simply Wall St utilizes a "Narrative" tool that allows investors to create custom financial forecasts and fair value estimates based on their own assumptions.

⚠️ This undervaluation calculation is subject to investor comfort levels regarding the long-term cash flow forecasts used in the model.

📝 The article concludes that Abbott Laboratories screens as an "UNDERVALUED" stock based on the provided DCF analysis methodology.

⚖️ The authors note that their analysis relies on historical data and analyst forecasts without incorporating the latest price-sensitive announcements or qualitative material.

Bullish Signals
  • Abbott Laboratories scores 5 out of 6 on Simply Wall St's valuation checklist, indicating strong fundamental strength.
  • According to a Discounted Cash Flow model, Abbott is estimated to be undervalued by approximately 35.7%, with an intrinsic value of $135.30 compared to the recent share price of around $87.01.
  • The company has generated about $7.1 billion in Free Cash Flow over the last twelve months, and analysts project this to grow to $14.8 billion by 2035.
  • Abbott's current P/E ratio of 24.24x is trading below its proprietary Fair Ratio of 30.37x, suggesting a potential upside opportunity.
  • The stock trades at a slightly lower multiple than the Medical Equipment industry average (23.87x vs 24.24x) but significantly below the peer group average of 33.24x.
Risk Factors
  • The stock has experienced significant share price weakness, declining 4.2% over the last week and a staggering 33.7% over the last year.
  • Abbott Laboratories is lagging behind its industry peers, recording a -33.7% return while its peer group trades at an average P/E ratio significantly higher at 33.24x versus Abbott's 24.24x.
  • Recent headlines have focused on Abbott without any single company-specific event driving the changes, indicating broad market sentiment issues affecting large healthcare stocks that are not related to specific company performance.
  • Analyst forecasts only extend explicitly to 2028, with long-term projections extrapolated further out to 2035, introducing uncertainty into the valuation model based on distant future cash flows.
  • The analysis explicitly notes that its fair value estimates may not factor in the latest price-sensitive company announcements or qualitative material, which could present a bearish risk if overlooked.
Full Analysis
Abbott Laboratories (ABT) is currently trading at approximately $87.01, representing a 33.7% decline over the last year and nearly a third off its 52-week high of roughly $136. The article analyzes whether this share price weakness presents a buying opportunity by examining valuation metrics that suggest the stock may be undervalued. Using a Discounted Cash Flow (DCF) model with a two-stage Free Cash Flow to Equity approach, analysts estimate an intrinsic value of $135.30 per share based on projections extending through 2035, indicating the stock is roughly 35.7% undervalued relative to current market prices. From a traditional multiple perspective, Abbott trades at a Price-to-Earnings (P/E) ratio of 24.24x. This compares favorably against both its medical equipment industry average of 23.87x and a peer group average of 33.24x, though it remains below Simply Wall St's proprietary Fair Ratio estimate of 30.37x. The report also contextualizes the recent stock performance as being influenced by broader healthcare sector sentiment rather than specific company events, while noting the company maintains strong positions in medical devices and diagnostics. The analysis concludes with a qualitative assessment tool called "Narratives," which allows investors to incorporate their own views on competitive positioning and future growth into custom fair value estimates, acknowledging that different risk assumptions can lead to varying conclusions. The content explicitly states that this is general analysis based on historical data and forecasts rather than specific financial advice, though it highlights the discrepancy between current market pricing and fundamental valuations derived from cash flow models.